Company Profile

GenVec Inc
Profile last edited on: 3/11/20      CAGE: 3BBG0      UEI:

Business Identifier: A biopharmaceutical company, which develops novel gene-based therapeutic drugs and vaccines
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

910 Clopper Road Suite 220n
Gaithersburg, MD 20878
   (240) 632-0740
Location: Single
Congr. District: 06
County: Montgomery

Public Profile

In January 2017, GenVec (NASDAQ:GNVC) a clinical-stage company and early involved in the development of AdenoVerse™ gene delivery technology. was acquired by Intrexon Corporation. Intrexon indicated intend to integrate and expand upon GenVec's expertise in adenoviral vectors and cGMP drug product manufacturing to enhance its broad gene transfer capabilities that encompass multiple viral and non-viral platforms. The combined technologies have the potential to yield the next generation of adenoviral (AdV) delivery through the creation of a scalable manufacturing platform utilizing helper-dependent adenovirus with significantly higher payload capacity of >30kb, as compared to current viral delivery methods ranging from 4.5kb – 9kb. With a storng SBIR involvement, GenVec, Inc. has been engaged in the development and commercialization of therapeutic proteins to treat diseases, including cancer, heart disease, and diseases of the eye. The company develops product candidates, such as TNFerade for oncology, BIOBYPASS for heart disease, cell therapy for cardiac repair, and AdPEDF program for ophthalmology. It is also collaborating with the U.S. Government for the development of vaccine candidates for HIV, SARS, malaria, and dengue virus. Its product candidate, TNFerade, which is in three Phase II trials, is used for the treatment of locally advanced pancreatic cancer, nonmetastatic esophageal cancer, and rectal cancer. The BIOBYPASS product candidate has completed a Phase II trial in patients with heart diseases. Its Cell Transplantation Therapy is in Phase I trials for the treatment of congestive heart failure; and AdPEDF, is in Phase I trial for the treatment of wet age-related macular degeneration, a cause of blindness in individuals over the age of 50. In addition, the company is also developing cell transplantation technology for treating human diseases that are characterized by cell dysfunction or cell death. In 1994, the two gene therapy firms of GenVec and Theragen merged under the name of Gen

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2017 1 NIH $215,085
Project Title: In Vivo Editing for Hemophilia Gene Therapy
2013 2 NIH $589,058
Project Title: Adenovirus-Vectored Rsv Vaccine Not Inhibited By Maternal Immunity
2013 2 NIH $600,000
Project Title: Pre-Erythrocytic Stage Antigen Discovery For Malaria Vaccine Development
2011 2 NIH $3,069,048
Project Title: Production of Adenovector Based Vaccines
2010 2 NIH $500,313
Project Title: Development Of An Ad14 Vaccine

Key People / Management

  Douglas J Swirsky -- President And Chief Operating Officer

  Douglas E Brough -- Chief Scientific Officer

  Joseph T Bruder

  Bryan T Butman -- Senior Vice President, Development

  David A Einfeld

  Paul H Fischer -- President

  Jason Gall

  Charles Richter King

  Duncan L Mcvey

  Michael C Tucker -- Business Development

  Lisa L Wei